Latest news with #noninvasive
BBC News
9 hours ago
- Health
- BBC News
New ultrasound forecast to cut Addenbrooke's treatment times
NHS patents will be the first in Europe outside a trial setting to have access to a liver cancer treatment described as "cutting-edge and non-invasive".Addenbrooke's Hospital in Cambridge will start using a histotopsy system, an ultrasound treatment that can be delivered in a single short session. It could potentially take no longer than 30 minutes with limited or no pain and a quick Sinker, chief executive of Cambridge University Hospitals (CUH), said the technology could make a "huge difference" and reduce cancer treatment times. The Edison Histotripsy System, made by US-based HistoSonics, is expected to be fully installed at CUH later this year. It will initially be used to treat patients with primary and secondary liver tumours, and research is exploring its potential on treating other hard-to-reach Sinker said: "Histotripsy is an exciting new technology that will make a huge difference to patients. "By offering this non-invasive, more targeted treatment, we can care for more people as outpatients and free up time for surgeons to treat more complex cases. "The faster recovery times mean patients will be able to return to their normal lives more quickly, which will also reduce pressure on hospital beds, helping us ensure that patients are able to receive the right treatment at the right time." The incisionless surgery uses pulsed sound waves to create "bubble clouds" from gases present in the targeted form and collapse in microseconds, creating mechanical forces able to destroys tumours without surgery, scalpels or has been procured following a donation to the University of Cambridge from the Li Ka Shing Foundation, a supporter of cancer research at the Deborah Prentice, vice-chancellor of the university, said: "Through his longstanding support of cancer research at Cambridge, Sir Ka-shing Li continues to make a significant impact on outcomes for cancer patients. "Cutting-edge technology such as this histotripsy machine allows Cambridge to remain at the forefront of understanding and treating cancer, a position we aim to strengthen further with Cambridge Cancer Research Hospital."Previously, 23 patients from Europe were recruited in a histotripsy clinical trial. More than 1,500 patients worldwide have received the treatment, mainly in the United States. Follow Cambridgeshire news on BBC Sounds, Facebook, Instagram and X.
Globe and Mail
a day ago
- Business
- Globe and Mail
Intelligent Bio Solutions (NASDAQ: INBS) Showcases Portable Drug Testing System at RISE25
The company's non-invasive fingerprint drug screening system uses fingerprint sweat to screen for drugs such as cannabis, cocaine, methamphetamine, and opiates. Results are available in under ten minutes, supporting faster, on-site decision-making in treatment and justice settings. INBS is pursuing FDA approval and further entry into the U.S. market, where it currently operates in a Forensic Use Only capacity. The company has over 450 active accounts in 24 countries, targeting sectors such as healthcare, justice, and workplace safety. INBS partnered with SMARTOX, a U.S. distributor, to connect with stakeholders in criminal justice and addiction recovery. Intelligent Bio Solutions (NASDAQ: INBS), a medical technology company specializing in rapid, non-invasive testing solutions, recently attended the RISE25 conference to demonstrate its portable Intelligent Fingerprint Drug Screening System, continuing its push into the U.S. market for rapid, non-invasive screening technologies ( The event, held May 28–31 in Florida, attracted over 7,000 professionals from the fields of addiction treatment, mental health, and criminal justice. The conference has become a national gathering point for… Read More>> NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: Corporate Communications
Yahoo
3 days ago
- Business
- Yahoo
HIRONIC Successfully Hosts First Asia Innovation Summit 2025
SEOUL, South Korea, June 7, 2025 /PRNewswire/ -- HIRONIC, a global leader in non-invasive medical aesthetic technology, has successfully hosted its inaugural 'HIRONIC Innovation Summit 2025. Asia Edition' in Bangkok, Thailand on June 5th. The event brought together approximately 100 medical professionals and medical distribution industry representatives from South Korea, Thailand, Vietnam, Malaysia, Indonesia, Myanmar, and other countries. Across four in-depth clinical sessions, speakers presented the latest approaches to skin rejuvenation, covering multi-layered face and body lifting, advanced scar treatment, and next-generation needle-free drug delivery technologies. One of the keynote lectures was delivered by Dr. Wonkyu Hong, Director and dermatologist at Human Dermatology Clinic and Executive Director of the Human Clinical Trial Center in South Korea. Dr. Hong explored the rapidly evolving role of needle-free technology in aesthetic medicine, sharing his clinical experience while emphasizing both its therapeutic advantages and its significant market growth potential driven by increasing patient demand for non-invasive rejuvenation solutions. Dr. Thitikom Limrattanamekha, founder and CEO of Optima Aesthetics in Thailand and an experienced laser specialist in scar treatment, skin quality improvement, and pigmentation management, shared his expertise on combining pico laser and RF microneedling to achieve highly effective outcomes in complex scarring cases. His presentation highlighted how advanced combination protocols are reshaping non-surgical treatment approaches and expanding therapeutic options for physicians worldwide. The symposium also provided a platform to showcase the clinical advancements and growing market relevance of HIRONIC's flagship export technologies, including New Doublo™, PICOHI™, and the latest needle-free delivery system Synerjet PRO™. Sasha Borovtsova, Head of Global Marketing Office at HIRONIC, stated, "This summit not only showcased the real-world clinical applications of our technologies but also underscored the accelerating global demand for safer, more versatile, and highly effective aesthetic solutions. As innovation continues to drive market growth, HIRONIC remains committed to advancing technology and strengthening global expertise and partnerships through events like the HIRONIC Innovation Summit." About HIRONIC Headquartered in South Korea, HIRONIC is a leading global manufacturer of medical aesthetic devices, specializing in HIFU, RF, laser, and needle-free technologies. With a presence in over 80 countries, HIRONIC has introduced iconic devices such as Doublo™, Doublo Gold™, and New Doublo 2.0™ to the international market. View original content to download multimedia: SOURCE HIRONIC Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Associated Press
23-05-2025
- Business
- Associated Press
IBN Coverage: Intelligent Bio Solutions (NASDAQ: INBS) to Showcase Fingerprint Drug Testing at RISE25 Conference
This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community. LOS ANGELES, CA - May 22, 2025 ( NEWMEDIAWIRE ) - Intelligent Bio Solutions (NASDAQ: INBS) announced its participation at the RISE25 conference in Kissimmee, Florida, from May 28 to 31, 2025, where it will support U.S. distribution partner SMARTOX. INBS will demonstrate its Intelligent Fingerprinting Drug Screening System - a non-invasive, rapid test using fingerprint sweat to detect substances like THC, cocaine, methamphetamine, and opiates. With results delivered in under 10 minutes, the technology is well-suited for treatment courts and justice applications. INBS views the event as a key platform to engage stakeholders as it advances toward U.S. market entry. To view the full press release, visit About Intelligent Bio Solutions Inc. Intelligent Bio Solutions Inc. is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company's current customer segments outside the US include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners. NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: The latest news and updates relating to INBS are available in the company's newsroom at Forward Looking Statements Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading 'Risk Factors' discussed under the caption 'Item 1A. Risk Factors' in Part I of the Company's most recent Annual Report on Form 10-K or any updates discussed under the caption 'Item 1A. Risk Factors' in Part II of the Company's Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this article in making an investment decision, which are based on information available to us on the date hereof. All parties undertake no duty to update this information unless required by law. About IBN IBN is a cutting-edge communications and digital engagement platform providing tailored Platform Solutions for select private and public companies. Over the course of 19+ years, IBN has introduced over 70 investor facing brands to the investment public and amassed a collective audience of millions of social media followers. These distinctive investor brands amplify recognition and reach as well as help fulfill the unique needs of our rapidly growing and diverse base of client-partners. IBN will continue to expand our branded network of influential properties as well as leverage the energy and experience of our team of professionals to best serve our clients. IBN's Platform Solutions provide access to: (1) our Dynamic Brand Portfolio (DBP) through 70+ investor facing brands; (2) article and editorial syndication to 5,000+ news outlets; (3) full-scale distribution to a growing Social Media Network (SMN) ; (4) a network of wire solutions via InvestorWire to effectively reach target markets and demographics; (5) Press Release Enhancement to ensure accuracy and impact; (6) a full array of corporate communications solutions; and (7) total news coverage solutions. For more information, please visit Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: Media Contact IBN Los Angeles, California 310.299.1717 Office [email protected] View the original release on
CBS News
22-05-2025
- Health
- CBS News
New device developed by University of Chicago scientists could find medical answers without blood tests
A lot of people don't like getting their blood drawn, but it is often the only way to obtain medical answers. But scientists at the University of Chicago have developed a device that could obtain medical results without needles. The device is called the airborne biomarker localization engine, or ABLE. Researchers say the device could detect airborne viruses or bacteria in hospitals or public spaces — and thus improve neonatal care, or allow people with diabetes to get a reading on their blood glucose levels just with their breath rather than a finger stick. Professor Bozhi Tian of the University of Chicago explained that the ABLE works through the simple process of changing the state of matter. For generations, the best way to detect molecules has been through liquids such as blood — and even rapid COVID tests involve using droplets of liquid. Looking for particles in the air is much harder because they're so diffuse, but the ABLE has a solution for that, Tian said. "So imagine you have very diluted molecules in air that regular sensors find hard to detect because they are too thinly spread," he said. "Now our device, our ABLE device, solves this problem by cooling the air to turn water vapor into droplets — like how dew forms on a cold window. So this process collects and also concentrates these airborne molecules into the water droplets, making them easier to detect with simple tests, or sensors that are already available, such as the color-changing strips." The new device created by scientists at the University of Chicago to detect molecules in air samples. The technology could one day be used to diagnose a wide array of diseases. Bozhi Tian Tian said the device uses a special water-repellent, or superhydrophobic, surface so the droplets can bounce and be collected. "This can increase the sensitivity by thousands to millions of times compared to the regular gas sensors," he said. Tian said he was first inspired to get started on the project when he visited the Stephen Family Neonatal Intensive Care unit at UChicago's Comer Children's Hospital right after the COVID pandemic. He said he thought, "After seeing those preterm babies struggling, I started to ask myself, as a material scientist, can I actually design some gentle and no-contact sensors to monitor the health — without adding stress or discomfort to the preterm infants?" Tian said he was also inspired by some examples in nature of organisms that use a water-repellent surface to capture liquid from the environment. "For example, some desert beetles, they actually survive by capturing some tiny droplets of moisture from fog — utilizing their very unique and highly water-repellent surface," he said. "Now, another example could be a lotus leaf. The lotus leaves remain clean and also dry, despite this constant exposure to water. And this is because of remarkable super-hydrophobic textures Now, inspired by those ingenious biological designs, we adopted the concept of the superhydrophobic surface to have this condensation system for sensors." Researchers hope the ABLE can optimize care for premature infants without blood tests or other invasive means. There could be numerous other uses, but UChicago noted that the ability to detect airborne molecules in this fashion is so new that scientists don't yet know what molecules they should be looking for. The group is now working with a doctor who treats inflammatory bowel disease, UChicago said. IBD patients may have markers of inflammation in their breath that the ABLE could detect. Mechanical engineer Jingcheng Ma, an assistant professor at the University of Notre Dame who worked on the study, also noted that implications of the ABLE when it comes to revealing new principles of physics. "This work might start many new studies on how these airborne impurities affects phase change behaviors, for example, and the new physics can be used for many applications," Ma said in a UChicago News story by Louise Lerner. The co-authors of the study on the ABLE also included UChicago scientists Megan Laune, Pengju Li, Jing Lu, Jiping Yue, Yueyue Yu, Jessica Cleary, Kaitlyn Oliphant, and Zachary Kessler.
